For AMD, treatments primarily focus on managing disease progression, with anti‐vascular endothelial growth factor (VEGF) injections being the standard care for wet AMD, while dry AMD relies mainly on nutritional supplements and preventive measures.[378, 379] RP treatment approaches include gene therapy (notably Luxturna for specific genetic mutations), experimental stem cell therapies, and various neuroprotective strategies.[380] However, both conditions still lack definitive cures, driving the development of more precise treatments. This evidence concerns the gene VEGFA and dry age related macular degeneration.